GO
Loading...

Valeant Pharmaceuticals International Inc

More

  • April 21- Some of the top investors at Mylan NV, including Paulson& Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter. Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania- based company.

  • Iron ore gloom chills Fortescue bond sale Thursday, 19 Mar 2015 | 4:37 AM ET

    NEW YORK/ MELBOURNE, March 19- A treacherous snowstorm snarled flights the day Fortescue Metals Group's CFO touched down in New York on a mission to tap the loan market for $2.5 billion to help the world's no.4 iron ore miner ride out collapsing iron ore prices. The timing was terrible- as Stephen Pearce battled through the frigid Manhattan weather, another squall...

  • Junk bond market defies skeptics Wednesday, 18 Mar 2015 | 11:28 AM ET
    Traders work on the floor of the New York Stock Exchange.

    There has been no sting in the tail for investors willing to bet on US high-yield bonds during 2015, the Financial Times reports.

  • After-hours buzz: Jumei, American Air & more Monday, 16 Mar 2015 | 5:46 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Monday's after-hours buzz: Jumei, American Air & more.

  • March 16- U.S. stocks rallied on Monday as the U.S. dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike. The S&P healthcare sector led gains in the S&P 500. It jumped 2.2 percent, helped by a 5.7 percent price increase in shares of Amgen to $163.03, following promising data in studies of a new class of...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher as investors cheered a pause in the dollar rally and eyed renewed weakness in oil prices ahead of Wednesday's Fed meeting.

  • "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. The S&P healthcare sector was up 1.9 percent, helped by a 3.6 percent price increase in shares of Amgen to $159.73, following promising data in studies of a new class of cholesterol-reducing drugs.

  • *Empire State manufacturing data miss estimates. "It's just a little bit of relief from last week's selloff," said Joseph Benanti, managing director, sales and trading of Rosenblatt Securities in New York. Until Fed Chair Janet Yellen's statement on Wednesday afternoon, Benanti is expecting light volume.

  • *Empire State manufacturing data misses estimates. March 16- U.S. stocks opened higher Monday and the benchmark S&P 500 rebounded after three weeks of losses as the euro strengthened against the dollar, easing some concerns over the impact of a robust greenback on corporate earnings. A recovery in the euro was reassuring investors, said Nick Colas, chief market...

  • US STOCKS-Wall St futures rise as euro recovers Monday, 16 Mar 2015 | 9:02 AM ET

    *Empire State manufacturing data miss estimates. March 16- U.S. stock index futures were up on Monday, putting the benchmark S&P 500 on track for a rebound after three weeks of losses, as currency markets helped reassure U.S. investors concerned about how a strong dollar would hurt earnings. A recovery in the euro was reassuring investors as a rapidly rising U.S....

  • BUZZ-SALIX PHARMACEUTICALS PLC: VALEANT RAISES ALL-CASH OFFER@** American drugmaker's shares up 2 pct at $173. **Canadian drugmaker Valeant Pharmaceuticals International Inc raised its offer to buy Salix to $173 from $158 in cash. **Sources told Reuters on Friday Valeant was working with its top shareholders on plans to raise its offer for Salix, sending Dublin-...

  • Valeant, Salix agree to cash deal of $173 a share Monday, 16 Mar 2015 | 7:56 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals agreed to buy Salix Pharmaceuticals for $173 per share Monday morning.

  • Valeant won't overpay for Salix: Bill Ackman Friday, 13 Mar 2015 | 12:33 PM ET
    Valeant Pharmaceuticals International’s headquarters in Mississauga, Ontario, Canada, is shown in this March 30, 2011 photo.

    Valeant chief Michael Pearson won't pay too much for Salix, which earlier this week received a competing offer from Endo, Bill Ackman tells CNBC.

  • Traders on the floor of the New York Stock Exchange.

    U.S. stocks closed mildly lower on amid continued concern over dollar gains and the timing of a Fed interest rate hike.

  • Early movers: QCOM, CS, URBN, SWKS, PG & more Tuesday, 10 Mar 2015 | 7:49 AM ET

    Some of the names on the move ahead of the open.

  • After-hours buzz: Urban Outfitters, Casey's & more Monday, 9 Mar 2015 | 5:19 PM ET
    Traders on the floor of the New York Stock Exchange, December 1, 2014.

    Check out the companies making headlines after the bell Monday: Urban Outfitters, Qualcomm, Casey's & more.

  • Ackman's $20 billion Pershing Square Capital Management hedge fund began building up the $3.3 billion stake, only months after its vocal effort to help Valeant buy Botox-maker Allergan failed, a source familiar with the investment told Reuters. His Pershing Square has notched big wins at railway firm Canadian Pacific and shopping mall operator General...

  • Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed. His Pershing Square has notched big wins at railway Canadian Pacific and shopping mall operator General Growth Properties, and also made money...

  • 'Risky' places where investors are finding returns Friday, 6 Mar 2015 | 8:27 AM ET

    A new research report has shone light on the corners of the market that investors have flocked to in search some return.

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...